ClinicalTrials.gg
CompletedNCT00801788Updated Aug 29, 2016

Single Dose Pharmacokinetics of Egalet® Oxycodone

A Phase 1 interventional study of Oxycodone hydrochloride and Oxycodone hydrochloride in Pain, sponsored by Egalet Ltd. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-29.

Sponsored by Egalet Ltd · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing oxycodone in Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Oxycodone · Pain.

Enrollment
44th of 50
16 · median 67
Started
2008
with 1 other
Phase 1
10 of 50
2 open now
Registered
7th of 50
by date

Among the 50 studies testing oxycodone in Pain, this one is the 44th largest by enrollment, is one of 2 that started in 2008, is one of 10 in phase 1, and was the 7th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 50 studies testing oxycodone in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing oxycodone in Pain, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the pharmacokinetic profile of different Egalet® oxycodone formulations and compare to a marketed oxycodone product.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main inclusion criteria:

  • ≥18 years and ≤55 years
  • Non-smoker
  • ≥18.0 and ≤30.0

Main exclusion criteria:

  • Any abnormality or abnormal laboratory test results found during medical screening
  • History of allergic reactions to opioids or other related drugs
  • History of significant alcohol abuse or drug abuse
  • Use of any drugs known to inhibit hepatic drug metabolism
  • Pregnant or breast-feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Egalet® oxycodone Treatment A

    Single Dose Administration

    Drug: Oxycodone hydrochloride

  • Experimental
    Egalet® oxycodone Treatment B

    Single Dose Administration

    Drug: Oxycodone hydrochloride

  • Experimental
    Egalet® oxycodone Treatment C

    Single Dose Administration

    Drug: Oxycodone hydrochloride

  • Active comparator
    Active comparator

    Single Dose Administration

    Drug: Oxycodone hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate pharmacokinetics of Egalet® oxycodone. AUC0-t, AUC0-inf, Cmax, Residual Area, Tmax, T½ el,Kel,AUC 0-12 and AUC 0-24.

    Time frame: Single-dose evaluation

Secondary outcomes

  1. To evaluate safety and tolerability of Egalet® oxycodone. Hematology, biochemistry, urinalysis, vital signs (including pulse oximetry), and adverse event monitoring.

    Time frame: Single-dose evaluation

07

Study locations

1 site
  • Quebec, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Oct 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2008
First posted
Dec 4, 2008
Start
Sep 2008
Primary completionActual
Oct 2008
CompletionActual
Feb 2009
Last update
Aug 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00801788
Lead sponsor
Egalet Ltd
Responsible party
Sponsor
First posted
Dec 4, 2008
Start date
Sep 2008
Primary completion
Oct 2008
Completion
Feb 2009
Last update
Aug 29, 2016

Study contacts

Christine Andersen, M.Sc.
study director · Egalet A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion